ExploreWatchlistsPricing
  1. JP-listed companies
  2. Takeda Pharmaceutical Company Limited
  3. Financials
  4. Retained earnings

Takeda Pharmaceutical Company Limited (4502)

Market cap
¥8.92T
P/E ratio
57.3x
Takeda develops and manufactures innovative medicines for gastrointestinal diseases, rare diseases, oncology, neuroscience, vaccines, and plasma therapies worldwide.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndRetained earnings (Million JPY)YoY (%)
Mar 31, 20251,187,586-14.64%
Mar 31, 20241,391,203-9.73%
Mar 31, 20231,541,146+4.15%
Mar 31, 20221,479,716-2.00%
Mar 31, 20211,509,906+10.21%
Mar 31, 20201,369,972-12.71%
Mar 31, 20191,569,365+8.30%
Mar 31, 20181,449,122+3.18%
Mar 31, 20171,404,415-2.33%
Mar 31, 20161,437,921+9.17%
Mar 31, 20151,317,080

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat